Zobrazeno 1 - 10
of 130
pro vyhledávání: '"J. Lemery"'
Autor:
B. E. Lewandowski, C. M. Schkurko, R. S. Miller, R. W. Valentine, K. M. Calaway, J. D. Yang, D. J. Ebert, A. Sargsyan, V. Byrne, M. Walton, J. Lemery, R. Suresh, M. S. Thompson, B. D. Easter, K. R. Lehnhardt
Publikováno v:
Frontiers in Space Technologies, Vol 5 (2024)
Throughout the history of human spaceflight, spacefarers have experienced and reported the occurrence of medical conditions, including various illnesses and injuries. Therefore, future spaceflight missions to the Moon and Mars will require the capabi
Externí odkaz:
https://doaj.org/article/9fe964fc65874d72a9168e24bed4de43
Publikováno v:
GeoHealth, Vol 4, Iss 8, Pp n/a-n/a (2020)
Abstract Anthropogenic climate change is influencing the incidence of dust storms and associated human exposure to coarse particulate matter (PM2.5–10) in the United States. Studies have found adverse health consequences related to dust exposure. T
Externí odkaz:
https://doaj.org/article/80387f3272cd46478549133f9c07c3f0
Autor:
Elizabeth S. Duke, Diana Bradford, Michelle Marcovitz, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Emily Nguyen, Lauren S. L. Price, Jeanne Fourie Zirkelbach, Yangbing Li, Youwei Bi, Jeffrey Kraft, Sarah E. Dorff, Barbara Scepura, Maritsa Stephenson, Idara Ojofeitimi, Abhilasha Nair, Yu Han, Zivana Tezak, Steven J. Lemery, Richard Pazdur, Erin Larkins, Harpreet Singh
Publikováno v:
Clinical Cancer Research.
On September 21, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo®, Eli Lilly and Company) for the treatment of adult patients with locally advanced or metastatic solid tumors with a rearranged
Autor:
Lola A. Fashoyin-Aje, Marc R. Theoret, Steven J. Lemery, Richard Pazdur, Shenghui Tang, Matthew D. Thompson, Hong Zhao, Elizabeth I. Spehalski, Rosane Charlab, Sirisha L. Mushti, Margaret Thompson, Leslie Doros, Vaibhav Kumar
FDA Benefit Risk Assessment and Summary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9e89b32ad021953ce08834133b2280
https://doi.org/10.1158/1078-0432.22489056
https://doi.org/10.1158/1078-0432.22489056
Autor:
Richard Pazdur, Rajeshwari Sridhara, Harpreet Singh, Wendy S. Rubinstein, Donna R. Rivera, Gregory H. Reaman, Pallavi S. Mishra-Kalyani, Steven J. Lemery, Adnan A. Jaigirdar, Nicole J. Gormley, Lola Fashoyin-Aje, Julia A. Beaver, Laleh Amiri-Kordestani, Marc R. Theoret, Paul G. Kluetz, Kirsten B. Goldberg, Yutao Gong, Julie A. Schneider
Supplementary Tables S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88c68586aec85b20a12e5d2498498ec8
https://doi.org/10.1158/1078-0432.22480349.v1
https://doi.org/10.1158/1078-0432.22480349.v1
Autor:
Richard Pazdur, Rajeshwari Sridhara, Harpreet Singh, Wendy S. Rubinstein, Donna R. Rivera, Gregory H. Reaman, Pallavi S. Mishra-Kalyani, Steven J. Lemery, Adnan A. Jaigirdar, Nicole J. Gormley, Lola Fashoyin-Aje, Julia A. Beaver, Laleh Amiri-Kordestani, Marc R. Theoret, Paul G. Kluetz, Kirsten B. Goldberg, Yutao Gong, Julie A. Schneider
The FDA Oncology Center of Excellence (OCE) is a leader within the agency in scientific outreach activities and regulatory science research. On the basis of analysis of scientific workshops, internal meetings, and publications, the OCE identified nin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19165a9b55b326de580540d3a15c7e6a
https://doi.org/10.1158/1078-0432.c.6530426.v1
https://doi.org/10.1158/1078-0432.c.6530426.v1
Autor:
M. Naomi Horiba, Sandra J. Casak, Pallavi S. Mishra-Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery, Lola A. Fashoyin-Aje
Publikováno v:
Clin Cancer Res
The FDA approved nivolumab on May 20, 2021, for the adjuvant treatment of completely resected (negative margins) esophageal or gastroesophageal junction cancer (EC/GEJC) in patients who had residual pathologic disease following chemoradiotherapy. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f802b4c663add72d06c7d997013928d3
https://europepmc.org/articles/PMC9771915/
https://europepmc.org/articles/PMC9771915/
Autor:
Timil H. Patel, Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Robert N. Schuck, Yangbing Li, Xinyuan Zhang, Jeanne Fourie Zirkelbach, Rosane Charlab, Jiang Liu, Yuching Yang, Steven J. Lemery, Richard Pazdur, Marc R. Theoret, Lola A. Fashoyin-Aje
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other re
Autor:
Sandra J. Casak, Shan Pradhan, Lola A. Fashoyin-Aje, Yi Ren, Yuan-Li Shen, Yuan Xu, Edwin Chiu Yuen Chow, Ye Xiong, Jeanne Fourie Zirklelbach, Jiang Liu, Rosane Charlab, William F. Pierce, Nataliya Fesenko, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery
Publikováno v:
Clin Cancer Res
On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af40300243294b5f12940579ab82ce88
https://europepmc.org/articles/PMC9250596/
https://europepmc.org/articles/PMC9250596/
Publikováno v:
Journal of environmental management. 310
Oil and natural gas are the largest primary global energy sources, and upstream gas emissions from these fuels can impact global climate change and local public health. This paper employs a public health-oriented perspective that reviews grey and aca